Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer is a phase 3 interventional study registered as NCT06712355 by BioNTech SE, with 621 participants planned, started 2025-02-03 and due to reach its primary completion in 2028-12. Interventions recorded: Pumitamig, Atezolizumab, Etoposide, Carboplatin (or cisplatin if carboplatin is not tolerated). Conditions listed: Extensive-stage Small-cell Lung Cancer. No results are recorded here; the registry entry is the source.